Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells

Blood

Volumn 95, Issue 7, 2000, Pages 2356-2363

  Patel, Divyen H ^a   Allay, James A ^a   Belt, Judith A ^a   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; METHOTREXATE; NITROBENZYLTHIOINOSINE; PEMETREXED; RALTITREXED; TRIMETREXATE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG RESISTANCE; FEMALE; GENE THERAPY; GENE TRANSFER; LEUKOCYTE COUNT; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROMYELOCYTE; RETROVIRUS;

EID: 0034176821     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2356     Document Type: Article

References (55)

1. Takimoto CH. Antifolates in clinical development. Semin Oncol. 1997;24-S18
2. Weber G Biochemical strategy of cancer cells and the design of chemotherapy G H. A. Clowes Memorial Lecture. Cancer Res 1983;43:3466-3492.
3. Fox M, Boyle JM, Kinsella AR Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer 1991;64:428-436.
4. Kinsella AR, Smith D, Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 1997;75: 935-945.
5. Cass CE Nucleoside transport. In. Georgopapadakou NH, ed. Drug Transport in Antimicrobial Therapy and Anticancer Therapy New York: Marcel Dekker; 1995 403-451.
6. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996;1286.153-181
7. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleosicte transport in normal and neoplastic cells Adv Enzyme Regul 1993;33:235-252
8. Kinsella AR, Smith D. Tumor resistance to anti-metabolites. Gen Pharmacol. 1998;30:623-626.
9. Warnick CT, Muzik H, Paterson ARP Interference with nucleoside transport in mouse lymphoma cells proliferating in culture Cancer Res. 1972, 32 2017-2022
10. Nelson JA, Drake S. Potentiation of methotrexate toxicity by dipyridamole Cancer Res 1984,44: 2493-2496.
11. Weber G, Jayaram HN, Pillwein K, Natsumeda Y, Reardon MA, Zhen YS. Salvage pathways as targets of chemotherapy Adv Enzyme Regul 1987; 26.335-352.
12. Zhen YS, Taniki T, Weber G. Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells [abstract] Oncol Res. 1992;4.73-78
13. Kolassa N, Jakobs ES, Buzzell GR, Paterson ARP Manipulation of toxicity and tissue distribution of tubercidin in mice by nitrobenzylthiomosine 5′-monophosphate Biochem Pharmacol. 1982; 33:1863-1874
14. El Kouni MH, Diop D, O'Shea P, Carlisle R, Sommadossi JP Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5-monophosphate for the treatment of schistosomiasis Antimicrob Agents Chemother 1989;33:824-827.
15. Willson JK, Fischer PH, Remick S, et al. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res 1989;49:1866-1870.
16. Wadler S, Subar M, Green MD, Wiernik PH, Muggia FM. Phase II trial of oral methotrexate and dipyridamole in colorectal carcinoma. Cancer Treat Rep. 1987;71:821-824.
17. Remick SC, Grem JL, Fischer PH, et al. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion Cancer Res 1990;50:2667-2672.
18. Zaniboni A, Simoncini E, Marpicati P, et al. 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study. J Chemother 1989;1: 266-268.
19. Budd GT, Jayaraj A, Grabowski D, et al Phase I trial of dipyridamole with 5-fluorouracil and folinic acid Cancer Res 1990;50:7206-7211.
20. Van Mouwerik TJ, Pangallo CA, Willson JK, Fischer PH. Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol. 1987;36:809-814
21. Grem JL, Fischer PH. Augmentation of 5-fluorouricil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res. 1985;45:2967-2972
22. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakley RL, Sorrentino BP. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood. 1997;90:3546-3554
23. Pinedo HM, Zaharko DS, Bull J, Chabner BA. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion Cancer Res. 1977;37:445-450.
24. Vogler WR, Mingioli ES, Garwood FA. The effect of methotrexate on granulocytic stem cells and granulopotesis Cancer Res 1973;33:1628-1633
25. Bogliolo GV, Lerza RA, Mencoboni MP, Saviane AG, Pannacciulli IM Toxicity of trimetrexate on hematopoietic progenitor cells in normal mice Anticancer Res 1988;8:229-231.
26. Stromhaug A, Slordal L, Warren DJ. Differential effects of the antifolates methotrexate, aminopterin and trimetrexate on murine hematopoietic progenitor cells. Br J Haematol 1996;92:514-520
27. Blau CA, Neff T, Papayannopoulou T The hematologic effects of folate analogs, implications for using the dihydrofolate reductase gene for in vivo selection. Hum Gene Ther. 1996;7 2069-2078.
28. Sorrentino BP. Drug resistance gene therapy. In: Brenner MK, Moen RC, eds. Gene Therapy in Cancer. New York. Marcel Dekker; 1996:189-230.
29. Sorrentino B P, Nienhius AW. The hematopoietic system as a target for gene therapy. In: Friedmann T. Development of Gene Therapy Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999.
30. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP. A gene transfer strategy for making bone marrow cells resistant to trimetrexate Blood 1996,87.2579-2587.
31. Corey CA, DeSilva AD, Holland CA, Williams DA Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood. 1990,75:337-343.
32. Zhao SC, Li MX, Banerjee D, et al Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther 1994;1 27-33.
33. Crawford CR, Patel DH, Naeve C, Belt JA. Cloning of the human equilibrative, nitrobenzylmer-captopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 1998;273:5288-5293.
34. Hawley RG, Lieu FH, Fong AZ, Hawley TS Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994;1:136-138.
35. Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WF Retrovtral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy Nucl Acids Res. 1992;20.1293-1299
36. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol. 1988;62:1120-1124.
37. Persons DA, Allay JA, Allay ER, et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells m vivo Blood. 1997;90:1777-1786
38. Patel M, Sleep SE, Lewis WS, et al Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants. Hum Gene Ther. 1997;8:2069-2077.
39. Lynch TP, Paran JH, Paterson AR. Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5′-monophosphate. Cancer Res. 1981;41:560-565.
40. Blackledge G New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ("Tomudex") Br J Cancer. 1998; 77(suppl 2):29-37.
41. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997,57:1116-1123.
42. Howell SB, Mansfield SJ, Taetle R. Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate. Cancer Chemother Pharmacol. 1981;5:221-226.
43. McDonald AC, Vasey PA, Adams L, et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res. 1998;4: 605-610
44. Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998,4.1136-1143.
45. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science. 1992; 257:99-103
46. Koc ON, Allay JA, Lee K, Davis BM, Reese JS, Gerson SL. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol. 1996;23:46-65
47. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996;87:1097-1103.
48. Tong Y, Liu-Chen X, Ercikan-Abali EA, et al. Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis: generation of mutants that confer resistance to raltitrexed, Thymitaq and BW1843U89. J Biol Chem. 1998,273:31,209-31,214.
49. Flandis DM, Loeb LA. Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases. J Biol Chem 1998; 273:25,809-25,817.
50. Allay J, Dumenco L, Koc O, Liu L, Gerson SL. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosurea resistance to hematopoietic cells. Blood. 1995; 85:3342-3351.
51. Mortiz T, Mackay W, Glassner BJ, Williams DA, Samson L Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res 1995;55. 2608-2614.
52. + cells to protect them against alkylating agents. Hum Gene Ther. 1997,8.1901-1910.
53. Marina NM, Belt JA. Effect of nucleoside transport inhibitors on thymidine salvage and the toxicity of nucleoside analogs in mouse bone marrow granulocyte-macrophage progenitor cells. Cancer Commun. 1991;3:367-372.
54. May C, Gunther R, McIvor RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood. 1995,86:2439-2448.
55. Zhao SC, Banerjee D, Mineishi S, Bertino JR. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Hum Gene Ther. 1997;8:903-909.